Attached files
file | filename |
---|---|
EX-3.1B - EXHIBIT 3.1B - Anika Therapeutics, Inc. | exh_31b.htm |
EX-3.1E - EXHIBIT 3.1E - Anika Therapeutics, Inc. | exh_31e.htm |
EX-3.1C - EXHIBIT 3.1C - Anika Therapeutics, Inc. | exh_31c.htm |
EX-3.1A - EXHIBIT 3.1A - Anika Therapeutics, Inc. | exh_31a.htm |
EX-31.2 - EXHIBIT 31.2 - Anika Therapeutics, Inc. | exh_312.htm |
EX-32.1 - EXHIBIT 32.1 - Anika Therapeutics, Inc. | exh_321.htm |
EX-31.1 - EXHIBIT 31.1 - Anika Therapeutics, Inc. | exh_311.htm |
EX-21.1 - EXHIBIT 21.1 - Anika Therapeutics, Inc. | exh_211.htm |
EX-10.16 - EXHIBIT 10.16 - Anika Therapeutics, Inc. | exh_1016.htm |
EX-10.17 - EXHIBIT 10.17 - Anika Therapeutics, Inc. | exh_1017.htm |
EXCEL - IDEA: XBRL DOCUMENT - Anika Therapeutics, Inc. | Financial_Report.xls |
10-K - FORM 10-K - Anika Therapeutics, Inc. | f10k_031215.htm |
EXHIBIT 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 333-06275, 333-66831, 333-79047, 333-58264, 333-110326, 333-160102, 333-176103 and 333-190597) of Anika Therapeutics, Inc. of our report dated March 13, 2015 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 10-K.
/s/ PricewaterhouseCoopers LLP
Boston, Massachusetts
March 13, 2015